Compare Best Buy Co Inc (BBY) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs DexCom, Inc. — how do they compare? Best Buy Co Inc trades at $82.94 (market cap $17.55B), while DexCom, Inc. trades at $89.38 (market cap $33.79B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Best Buy Co Inc pays a 4.61% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| BBY | DXCM | |
|---|---|---|
Market Cap | $17.55B | $33.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $89.53 |
52-Week Low | $55.52 | $54.84 |
Enterprise Value | $19.93B | $33.24B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBY trades at $82.43, up 0.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 39.1% ROE and trades at a P/E of 15.42, below the sector average. Recent news includes leadership changes and store format tests aimed at growth.
Outlook is mixed: analyst consensus is a hold with a $84.31 price target, but risks include declining revenue and competitive pressures. Upside potential exists if new strategies boost sales, while downside is capped by solid cash flow and dividend payments.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
